Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Leukemia. 2020 Jan 3;34(6):1563–1576. doi: 10.1038/s41375-019-0693-4

Fig. 2. Survival outcomes.

Fig. 2

a Median overall survival (OS) was 27.1 months (95% CI: 18.9, N/A) versus 33.8 months (95% CI: 20.5, N/A) for the whole cohort and pomalidomide-treated patients, respectively. b Median disease-free survival (DFS) was 20.6 months (95% CI: 8.2, NA) versus 27.1 months (95% CI: 8.2, N/A) for the whole cohort and pomalidomide-treated patients, respectively. c median event-free survival (EFS) was 8.3 months (95% CI: 6.0, 17.2) versus 9.4 months (95% CI: 7.1, NA) for the whole cohort and pomalidomide-treated patients, respectively.